NCT01389362

Brief Summary

There is now a global epidemic of diabetes and obesity affecting more than 300 million people worldwide with Asia in the forefront. In Hong Kong, diabetes affects more than 10% of the population. Patients with diabetes have a 12-25% lifetime risk of developing a foot ulcer.The abnormal metabolic milieus of hyperglycemia, hyperlipidemia, hypertension, pro-thrombotic state and chronic inflammation in diabetes causes atherosclerosis.A significant proportion of subjects have underlying peripheral arterial disease and neuropathy. These subjects are at great risk of developing infective foot ulceration secondary to impaired vascular supply, sensory loss and minor trauma.Without prompt and proper medical treatment, these infective ulcers will deteriorate leading to gangrene and limb amputation. In-vitro and in-vivo studies revealed that 5 out of the 12 herbs were effective in promoting fibroblast proliferation and angiogenesis. To minimize potential drug interactions and adverse effects from multiple components in a recipe of Traditional Chinese Medicine (TCM), the investigators have developed a simplified formula from the 12 herbs consisting of only two herbs. In this proof-of-concept study, the investigators hypothesize that the novel recipe of herbal medicine will expedite healing of early foot ulcer by promoting vascularisation and granulation as well as modulating inflammatory response.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started May 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2009

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 6, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 8, 2011

Completed
Last Updated

July 28, 2011

Status Verified

July 1, 2011

Enrollment Period

2 years

First QC Date

July 6, 2011

Last Update Submit

July 27, 2011

Conditions

Keywords

Diabetesfoot ulcerChinese herbal medicine

Outcome Measures

Primary Outcomes (1)

  • Resolution/progression of foot ulcer based on PEDIS

    6 months

Secondary Outcomes (1)

  • Hospital admission/attendance/stay

    6 months

Study Arms (2)

Chinese Herbal Medicine

ACTIVE COMPARATOR

2 sachets of Chinese Herbal Medicine to be taken daily

Drug: Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)

Placebo arm

PLACEBO COMPARATOR

2 sachets to be taken daily

Drug: Placebo comparator

Interventions

2 sachets to be taken daily

Chinese Herbal Medicine

2 sachets to be taken daily

Placebo arm

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetic subjects with documented evidence of mild diabetic foot ulcer
  • Male or female patients attending Diabetic Clinics and/or Podiatry Clinics at the hospitals of the New Territories East Cluster
  • Aged between 20 and 75 years old inclusive
  • All patients should be on stable dose of medication 4 weeks prior to enrolment
  • Written informed consent
  • If the patient is a woman of child-bearing potential, she must agree to use adequate method of contraception throughout the study period, unless surgically sterilized.

You may not qualify if:

  • Patients with end-stage renal disease as defined by the need for dialysis or on renal replacement program
  • Patients with advanced diabetic eye disease as defined by the history of laser therapy, retinal detachment or vitreous hemorrhage
  • Pregnancy, breast feeding, or patient has plans of becoming pregnant during the study period.
  • Known allergy to TCM drugs
  • Contraindication or intolerance to use of aspirin, statin , ACEI or ARB
  • History of major gastrointestinal bleeding in the 5 years prior to consent
  • Congestive heart failure of any severity
  • Significant cardiovascular disease within 3 months of enrolment including acute coronary syndrome, cardiac revascularization procedure, transient ischemic attack and cerebrovascular accident
  • HbA1c ≥ 10%
  • Severe liver function impairment (≥ 3 ULN of ALT) and renal impairment (eGFR \< 30 ml/min/1.73 m2)
  • Investigational drugs within 30 days of enrolment
  • Patient taking any Chinese herbal medicine in the 8 weeks prior to enrolment into the study
  • Any other medical conditions that is considered as unsuitable for the study by investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diabetes and Endocrine Centre

Hong Kong SAR, Hong Kong SAR, China

Location

Related Publications (1)

  • Ko CH, Yi S, Ozaki R, Cochrane H, Chung H, Lau W, Koon CM, Hoi SW, Lo W, Cheng KF, Lau CB, Chan WY, Leung PC, Chan JC. Healing effect of a two-herb recipe (NF3) on foot ulcers in Chinese patients with diabetes: a randomized double-blind placebo-controlled study. J Diabetes. 2014 Jul;6(4):323-34. doi: 10.1111/1753-0407.12117. Epub 2014 Feb 24.

MeSH Terms

Conditions

Diabetic FootDiabetes MellitusFoot Ulcer

Interventions

rehmannia rootHuang Qi

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsEndocrine System DiseasesDiabetic NeuropathiesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesFoot Diseases

Study Officials

  • Juliana NA Chan, MBChB, FRCP

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 6, 2011

First Posted

July 8, 2011

Study Start

May 1, 2009

Primary Completion

May 1, 2011

Study Completion

May 1, 2011

Last Updated

July 28, 2011

Record last verified: 2011-07

Locations